Literature DB >> 8012951

Purification of an alpha class glutathione S-transferase from melphalan-resistant Chinese hamster ovary cells and demonstration of its ability to catalyze melphalan-glutathione adduct formation.

A G Hall1, E Matheson, I D Hickson, S A Foster, L Hogarth.   

Abstract

We have shown previously that a Chinese hamster ovary cell line (designated CHO-Chlr), generated by exposure to chlorambucil and demonstrating a greater than 20-fold collateral resistance to melphalan, showed increased expression of an alpha form of glutathione S-transferase (GST) associated with amplification of GST genes. Here, we demonstrate that GST purified from CHO-Chlr cells contains a form with a pI of 9, not present in CHO-K1 cells or Chinese hamster liver, which has the ability to accelerate the formation of glutathione-melphalan adducts. This result provides evidence that overexpression of the alpha class GST may be directly responsible for the development of resistance to bifunctional alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012951

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.

Authors:  P David Josephy
Journal:  Hum Genomics Proteomics       Date:  2010-06-13

2.  Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.

Authors:  Maria Antonietta Sabatino; Cristina Geroni; Monica Ganzinelli; Roberta Ceruti; Massimo Broggini
Journal:  Epigenetics       Date:  2013-06-14       Impact factor: 4.528

3.  The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients.

Authors:  S Ghazal-Aswad; L Hogarth; A G Hall; M George; D P Sinha; M Lind; A H Calvert; J P Sunter; D R Newell
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.